Bionaturis acts as CDMO (Contract Development and Manufacturing Organization) developing and manufacturing biological APIs by means of its FLYLIFE technology. From research to clinical material in compliance with cGMP standards. A multiproduct FLYLIFE-based manufacturing plant shows:
- Low capital investment and low fixed costs
- Minimum space demand
- High-versatile protein expression
- High yield
- High scale-up speed. Delivering first batch in less than 12 weeks
- Biological safety. Devoid compounds of animal origin
Designed to fully compliance with international cGMP guidelines. For human and animal applications.